trial · primary record
Bleomycin
Ann Arbor Stage I Hodgkin Lymphoma
| Phase | Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 159 |
| Primary completion | 2027-05-21 |
| Primary endpoint | 18-month Progression-free Survival (PFS) for Each Arm of Therapy |
| Registry ID | NCT03712202 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:34:23.755Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT03712202
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.